Population pharmacokinetics of digoxin in elderly patients

被引:0
作者
Rong Chen
Su-lan Zou
Ming-li Wang
Yan Jiang
Hui Xue
Chun-yan Qian
Zong-ling Xia
机构
[1] The First People’s Hospital of Changzhou,
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2013年 / 38卷
关键词
Digoxin; Elderly; Population pharmacokinetics; NONMEM;
D O I
暂无
中图分类号
学科分类号
摘要
This study was aimed at determining the population pharmacokinetics of digoxin and identifying factors that explain pharmacokinetic variability in elderly patients. The data of 142 elderly patients and 448 samples were collected after repetitive oral digoxin. Blood samples were drawn at various times after administration. Population pharmacokinetic analysis was performed using nonlinear mixed effects modelling program (NONMEM). A one-compartment model with first-order absorption and elimination was selected as the base model. The influence of demographic characteristics, biochemical and haematological indices as well as other commonly used co-medications were explored. The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h−1 (43.2 %) and 420 L (65.8 %), respectively. The residual variability was 31.6 %. CL/F decreased significantly with renal function, total body weight, calcium channel blockers or spironolactone co-therapy and symptom with congestive heart failure. The median parameter estimates from a nonparametric bootstrap procedure were comparable and within 5 % of the estimates from NONMEM. These results provide important information for clinicians to optimize digoxin regimens in elderly patients.
引用
收藏
页码:115 / 121
页数:6
相关论文
共 90 条
[1]  
Bauer LA(1996)Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations Ther Drug Monit 18 46-52
[2]  
Horn JR(2009)Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study Eur J Clin Pharmacol 65 1237-1243
[3]  
Pettit H(2007)Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration Pharmacotherapy 27 472-475
[4]  
Chan AL(2002)Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization Am J Ther 9 492-498
[5]  
Wang MT(2011)Calcium channel blockers J Clin Hypertens (Greenwich) 13 687-689
[6]  
Su CY(2011)Potentially harmful drug–drug interactions in the elderly: a review Am J Geriatr Pharmacother 9 364-377
[7]  
Tsai FH(2003)Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the digitalis in acute atrial fibrillation trial Eur J Clin Pharmacol 58 747-755
[8]  
DeVore KJ(1993)The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 21 735-750
[9]  
Hobbs RA(1977)Bioavailability of digoxin: some pitfalls and problems Int J Clin Pharmacol Biopharm 15 549-556
[10]  
EL Desoky ES(1992)Changes in the plasma levels and basic pharmacokinetic parameters of digoxin used in combination with gentamicin, amiodarone and spironolactone Folia Med (Plovdiv) 34 24-28